Oncology Medical News about Leukemia, Myeloid Leukemia, Myeloid, Chronic-Phase

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

New Ovarian Cancer Test Guides Surgical Decisions

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Nanotech Effort with Glioblastoma - Impressive or Impractical?

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation
Blood, 11/06/09

Nicolini FE et al. – The BCR–ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall (OS) and progression–free survival (PFS) for CML in chronic (CP), accelerated (AP), or blastic (BP) phase, and Ph+ ALL patients with T315I mutation. The results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.

<< Previous
Acute Ingestion of Long-Chain (n-3) Polyunsaturated Fatty Acids...

Next >>
Satraplatin: leading the new generation of oral platinum agents